InVivo Therapeutics 2010 Archive

Boston Bruins Foundation and InVivo Therapeutics Corporation Honor Thomas E. Smith, Check Presentation to Take Place Monday December 20, 2010
December 17, 2010
On Monday, December 20 the Boston Bruins Foundation and InVivo Therapeutics (OTCBB: NVIV) will present a check for $15,000 dollars to Thomas E. Smith, founder of the Thomas E. Smith Fight to Cure Paralysis Foundation. The presentation will take place on-ice during the second intermission of the Bruins/Ducks game at the TD Garden (100 Legends Way, Boston, MA 02114).
Read More

InVivo Therapeutics Holdings Corporation Names George Nolen Former CEO of Siemens as Lead Director
December 13, 2010
InVivo Therapeutics today announced that the companys Board of Directors has appointed George Nolen, former President and CEO of Siemens Corporation and a Director of InVivo, to the position of Lead Director, effective December 10, 2010.
Read More

InVivo Therapeutics Closes Oversubscribed Private Placement, Raising $13 Million
December 6, 2010
InVivo Therapeutics (OTCBB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that it has successfully closed a private placement offering of 13 million units of its securities for total gross proceeds of $13 million.
Read More

InVivo Therapeutics to Present at Lazard Capital Markets Annual Healthcare Conference
November 10, 2010
InVivo Therapeutics (OTCBB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that Frank Reynolds, CEO of InVivo, will be presenting at the Lazard Capital Markets Annual Healthcare Conference on Tuesday, November 16, 2010 at 3:40 P.M. Eastern Time at the St. Regis Hotel in New York City.
Read More

InVivo Therapeutics CEO to Address 5th Annual Working 2 Walk Science & Advocacy Symposium
November 9, 2010
InVivo Therapeutics (OTCBB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that Frank Reynolds, CEO of InVivo, will address the 5th Annual Working 2 Walk Science & Advocacy Symposium taking place November 11 through 13, 2010 in Phoenix, Arizona. Mr. Reynolds remarks, titled Changing the Face of Neuroscience: Are Stem Cells Really Required to Heal a Spinal Cord Injury? will be given at 9:10am ET on Friday, November 12.
Read More

InVivo Therapeutics Opens New Manufacturing and Development Facility in Medford, Massachusetts to Support First Human Clinical Trial
November 1, 2010
InVivo Therapeutics Corporation, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that it has signed a lease to open its first manufacturing and development facility in Medford, Massachusetts. The company expects to use this new facility to scale up the manufacturing process for its lead product candidate, a novel biocompatible polymer scaffolding device used to treat acute open-wound SCI.
Read More

InVivo Therapeutics Announces Reverse Merger and $10.5 Million Private Offering
Octoberr 27, 2010
InVivo Therapeutics Corporation, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced the successful completion of a reverse merger with InVivo Therapeutics Holdings Corp. InVivo, now headquartered in Cambridge, Massachusetts, will continue the business of InVivo Therapeutics as a wholly-owned subsidiary under the leadership of InVivo Therapeutics current management team, headed by Chief Executive Officer, Frank Reynolds. In completing the Merger, InVivo issued approximately 31.6 million shares of its common stock to the holders of InVivo Therapeutics common stock. The merged company will be quoted on the OTC markets under the symbol “NVIV” beginning Thursday, October 28, 2010..
Read More